Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
52,382,313
-
Total 13F shares
-
34,291,369
-
Share change
-
+2,389,359
-
Total reported value
-
$272,339,183
-
Price per share
-
$7.94
-
Number of holders
-
65
-
Value change
-
+$19,165,614
-
Number of buys
-
38
-
Number of sells
-
13
Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q1 2024
As of 31 Mar 2024,
TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,291,369 shares.
The largest 10 holders included
Lynx1 Capital Management LP, EcoR1 Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BVF INC/IL, BAKER BROS. ADVISORS LP, Propel Bio Management, LLC, VANGUARD GROUP INC, BlackRock Inc., Deer Management Co. LLC, and Alphabet Inc..
This page lists
65
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.